Brought to you by:
Study: Social support associated with better PAD health outcomes
Patients with peripheral arterial disease (PAD) reporting lower levels of social support experience worse health outcomes, a new Yale-led study finds. Social support is thought to bolster cardiovascular health by facilitating health-promoting behaviors and acting as a buffer against the…
New ESC guidelines combine peripheral arterial and aortic diseases for first time, emphasising interconnectivity of whole arterial system
The European Society of Cardiology (ESC) has today published its 2024 guidelines for the management of peripheral arterial and aortic diseases (PAAD), evaluating these vascular conditions together as part of the same cardiovascular system. The guidelines are aimed at cardiologists,…
SVS Foundation’s Step at VAM challenge raises more than $30,000
The recent Vascular Annual Meeting (VAM 2024) was more than a gathering of medical professionals to discuss advancements in vascular health. It featured the Step at VAM challenge, an inspiring event highlighting the importance of physical activity that raised over…
‘Choosing the right devices for the right patients’: Surgeon-scientist secures NIH funding to develop MRI technique for precision PAD care
Michael Conte, MD, recently used his 2024 Veith Lecture to call on young vascular surgeons on the peripheral arterial disease (PAD) frontlines to drive the space forward amid a great unmet need. The professor and chief of vascular and endovascular…
SCOREPAD seeks to address ‘alarmingly high’ mortality in CLTI patients with underlying coronary disease
A new research letter underscores the need to improve long-term survival following lower extremity revascularization for chronic limb-threatening ischemia (CLTI), setting out a randomized controlled trial to examine the impact of coronary artery ischemia testing in these patients. The letter,…
SVS urges revisions for independent cardiology certification board
The Society for Vascular Surgery (SVS) has expressed conditional support for cardiology establishing an independent certification board but objects to provisions in the current American Board of Cardiovascular Medicine (ABCVM) proposal as they conflict significantly with the mission and requirements…
Acellular tissue-engineered vessel granted FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue-engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This RMAT…
Grasping the nettle: The need to tackle PAD problem head on is huge, says 2024 Veith lecturer
Huge opportunities abound for vascular surgeons to take a leadership role on the frontlines of a developing peripheral arterial disease (PAD) treatment crisis in the U.S., says Michael Conte, MD, who gave the second annual Frank J. Veith Distinguished Lecture…
The top 10 most popular Vascular Specialist stories of June 2024
In June, the most read stories from Vascular Specialist included key reports from the 2024 Vascular Annual Meeting (VAM; June 19–22) covering TEVAR, CEA vs TCAR, PAD and CFA-reintervention, among others; Linda Harris’ placement as SVS vice president; the relationship…
Humacyte’s ATEV granted FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This…